Destination Maternity (DEST) Takeover Target by Orchestra-Premaman; Akebia Therapeutics (AKBA) Inks Mega-Deal


Shares of Destination Maternity Corp. (Nasdaq:DEST) climbed over 10% in pre-market trading Monday after Orchestra-Premaman S.A. disclosed in a regulatory filing with the SEC ( SC 13D ) a 13.3% stake (1,843,931 shares) in the company.

According to the SEC filing, Orchestra-Premaman informed Destination Maternity about its ownership-position in the company and requested to start discussions related to a previous takeover offer – which was rejected by Destination Maternity – for $25 million in cash and stock

DEST stock closed at $9.00 on Friday, up $0.36 (or +4.17%), and 284,697 of its shares exchanged hands during the day

Destination Maternity, the world’s leading maternity apparel retailer, has 13.86M Shares Outstanding, Market Capitalization (intraday) of $124.72M and DEST stock 52-week range is between $4.99 and $16.74 per share



Akebia Therapeutics, Inc. (Nasdaq:AKBA) said that it has entered into a collaboration agreement with Mitsubishi Tanabe Pharma Corporation (TYO:4508) for vadadustat, sending its shares up by more than 10% before the opening bell Monday

As part of the deal, Mitsubishi Tanabe will make payments totaling $100 million for costs related to the global late-stage program for the drug. The deal also calls for up to $250 million in sales-milestone payments for Akebia

AKBA stock finished Friday’s trading session at $9.75

Akebia Therapeutics, a biopharmaceutical company, has 30.63M Shares Outstanding, Market Capitalization (intraday) of $298.66M and AKBA stock one-year range is from $5.91 to $14.20 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at